Comparing the Use of a Mobile App and a Web-Based Notification Platform for Surveillance of Adverse Events Following Influenza Immunization: Randomized Controlled Trial.

Autor:	Bota AB; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Bettinger JA; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada., Sarfo-Mensah S; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Lopez J; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada., Smith DP; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Atkinson KM; Karolinska Institutet, Solna, Sweden., Bell C; CanImmunize Inc, Ottawa, ON, Canada., Marty K; Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC, Canada., Serhan M; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Zhu DT; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, CT, United States., McCarthy AE; Department of Medicine, University of Ottawa, Ottawa, ON, Canada., Wilson K; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; CanImmunize Inc, Ottawa, ON, Canada.; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.; Bruyère Research Institute, Ottawa, ON, Canada.
Jazyk:	angličtina
Zdroj:	JMIR public health and surveillance [JMIR Public Health Surveill] 2023 May 08; Vol. 9, pp. e39700. Date of Electronic Publication: 2023 May 08.
DOI:	10.2196/39700
Abstrakt:	Background: Vaccine safety surveillance is a core component of vaccine pharmacovigilance. In Canada, active, participant-centered vaccine surveillance is available for influenza vaccines and has been used for COVID-19 vaccines. Objective: The objective of this study is to evaluate the effectiveness and feasibility of using a mobile app for reporting participant-centered seasonal influenza adverse events following immunization (AEFIs) compared to a web-based notification system. Methods: Participants were randomized to influenza vaccine safety reporting via a mobile app or a web-based notification platform. All participants were invited to complete a user experience survey. Results: Among the 2408 randomized participants, 1319 (54%) completed their safety survey 1 week after vaccination, with a higher completion rate among the web-based notification platform users (767/1196, 64%) than among mobile app users (552/1212, 45%; P<.001). Ease-of-use ratings were high for the web-based notification platform users (99% strongly agree or agree) and 88.8% of them strongly agreed or agreed that the system made reporting AEFIs easier. Web-based notification platform users supported the statement that a web-based notification-only approach would make it easier for public health professionals to detect vaccine safety signals (91.4%, agreed or strongly agreed). Conclusions: Participants in this study were significantly more likely to respond to a web-based safety survey rather than within a mobile app. These results suggest that mobile apps present an additional barrier for use compared to the web-based notification-only approach. Trial Registration: ClinicalTrials.gov NCT05794113; https://clinicaltrials.gov/show/NCT05794113. (©A Brianne Bota, Julie A Bettinger, Shirley Sarfo-Mensah, Jimmy Lopez, David P Smith, Katherine M Atkinson, Cameron Bell, Kim Marty, Mohamed Serhan, David T Zhu, Anne E McCarthy, Kumanan Wilson. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 08.05.2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu